pnh might ice initi
outperform pt
initi outperform rate
pt apelli late-stag develop compani focus treatment diseas
mediat dysfunct complement system lead asset target
immun complement cascad develop phase program
geograph atrophi ga paroxysm nocturn hemoglobinuria pnh believ
well posit address high unmet need ga treatment
option current exist also address deeper unmet need defin orphan
blood disord pnh phase pnh studi fulli enrol readout decemb
phase studi ga enrol year anticip share could
re-rat favor come month
blockbust potenti ga base larg preval diseas unmet
need similar commerci dynam wet recent interest ga
reignit signific reinvest roch believ ga sale could
reach us alon compar regeneron eylea franchis
post-ultomori remain signific unmet need novel treatment
pnh differenti mechan action drug
shown best-in-class potenti address extravascular hemolysi associ
morbid address current therapi check suggest
minimum patient diseas inadequ control
potenti product pipelin statu underscor pervas
complement activ array diseas high unmet need
pnh repres sizabl market opportun program serv also
encourag proof concept target activ sever
diseas name autoimmun hemolyt anemia complement-depend
nephropathi driven action
approach pivot moment phase pnh decemb posit
compani signific inflect near-term second studi may
requir believ total clinic data pnh support potenti file
singl head-to-head pegasu studi
initi outperform pt sum-of-the-part ascrib
multipl valuat pnh ga cash equival make
balanc valuat translat risk-adjust valuat
share pnh ga valuat assum probabl
success pnh po ga
year price histori
develop pegcetacoplan
current phase develop
pnh geograph atrophi ga
found apelli base
analyst certif import disclosur see disclosur
inhibit potenti address
two potenti blockbust indic signific unmet
need ga pnh believ potenti
address meaning proport pnh market
alreadi commerci develop alexion
therapeut soliri eculizumab ultomiri
ravulizumab ga howev treatment exist
sever late-stag diseas believ opportun set
eye could rival potenti exceed
regeneron flagship eylea aflibercept franchis
constrast also face brand ranibizumab/brolucizumab
demonstr hemoglobin improv least
improv transfus independ compar
initi phase aiha studi
enrol phase derbi oak complet end
phase pegasu readout pnh decemb
phase derbi oak readout ga
initi data expans opportun complement-depend
initi phase studi aiha
updat soliri exclus eu
demonstr hemoglobin improv improv
transfus independ compar eculizumab phase
enrol phase derbi oak complet end
demonstr clinic signific benefit ga pnh
aiha
employ composit valuat methodolog biotechnolog compani util revenu multipl discount cash flow analysi
respect development-stag compani place greater weight revenu multipl compar dcf analysi due
latter sensit long-run assumpt price target blend revenu multipl calcul dcf
valuat
appli revenu multipl pnh multipl ga lie rang industri averag
probabl success drug approv pnh ga
appli discount rate aplss valuat line smid-cap biotech
clinic efficaci fail meet clinic efficaci endpoint program pnh ga aiha
clinic safeti safeti signal emerg clinic studi
manufactur risk manufactur issu could hinder regulatori approv limit penetr commerci market
regulatori risk regul rais addit requir concern around develop delay prevent regulatori approv
commercial/competitive/reimburs risk competit pressur develop asset could lower market potenti
negoti payor could limit market opportun
financ apelli may requir addit fund conduct addit studi commerci
late-stag develop compani target complement-
mediat diseas high unmet need apelli develop current phase
develop paroxysm nocturn hemoglobinuria pegasu geograph
atrophi derbi oak addit apelli on-going phase program
cold agglutinin diseas cad warm aiha program expect advanc
phase next month last compani also conduct studi
complement-depend nephropathi iga nephropathi igan lupu
nephriti ln primari membran nephropathi primari mn glomerulopathi
dens deposit diseas
initi coverag apelli outperform rate price target
next month valuat focus two lead indic
target pnh ultra-rar blood disord ga common devast ophthalm
condit without approv treatment inhibit potenti
address signific unmet current pnh popul also becom first-in-
class treatment geograph atrophi sever late-stag manifest dri
believ potenti address meaning proport pnh
market alreadi commerci develop alexion pharmaceut
therapeut soliri eculizumab ultomiri ravulizumab ga
treatment exist sever late-stag diseas howev believ opportun
set eye could rival potenti exceed regeneron flagship
eylea aflibercept franchis contrastingli also face brand
ranibizumab/brolucizumab gener compound avastin competit
complement inhibitor gain signific investor attent sinc meteor rise
pnh deliv underwhelm result believ led cool space
believ apelli program remain one compel competit
program pnh believ industri also begin greatli appreci
complement-medi diseas rest outsid pnh thu see except
larg opportun ga complement identifi key actor
pathophysiolog diseas approv therapi current exist
employ composit valuat methodolog biotechnolog compani util
revenu multipl discount cash flow analysi respect development-stag
compani place greater weight revenu multipl valuat compar
dcf analysi due latter sensit long-run assumpt
price target assumpt indic exhibit
strengthstarget valid drug activ three separ phase programsstrong biolog ground target complement-medi central posit cascad allow greater diseas coveragew estim patient remain undertreatedweaknessesga challeng diseas area drug developmentga may requir addit commerci effort build due lack treatmentsphysician develop signific experi therapi make sale potenti stickyopportunitiescomplet unmet need ga market due lack approv therapiesw estim billion opportun gapotenti achiev best-in-class statu estim billion dollar pnh market breadth diseas exist mediat uncontrol complement activationthreatscompetit biosimilar develop could shift market dynam pnhother treatment target cascad ions/rhhbi ionis-fb-lrxcould lower market potenti gatheoreticalrisk infect due target higher complement cascad
appli revenu multipl pnh estim peak revenu million
million us eu respect lie rang
industri averag includ addit opportun system administr
hematolog condit independ valu aiha
pois pivotal-stag develop note higher-than-averag revenu
multipl account expans opportun hematolog condit ascrib
multipl geograph atrophi royalti estim ex-u
commerci estim peak revenu billion million
royalti us row respect
probabl success drug approv pnh
geograph atrophi believ current avail data primari well key
secondari endpoint pnh strongli support success support higher-than-
programpeak revenuemultipleyearwaccvaluationposrisk-adj valuat /share totalpnh eu/row million except per share assumptionscurr ye share multipl tab pnh us eu/row us eu/row growth cash valu outstand per share per share million except per share outperform
averag probabl success phase program place slightli
conserv po geograph atrophi account potenti risk manufactur
complex pathophysiolog diseas ga
appli discount rate aplss valuat line smid-cap biotech
exhibit partsmultipl valuat per share
risk thesi follow
clinic efficaci fail meet clinic efficaci endpoint
program pnh ga aiha
clinic safeti safeti signal emerg clinic studi
manufactur risk manufactur issu could hinder regulatori approv limit
penetr commerci market
regulatori risk regul rais addit requir concern around
develop delay prevent regulatori approv
commercial/competitive/reimburs risk competit pressur
develop asset could lower market potenti negoti
payor could limit market opportun
financ apelli may requir addit fund conduct addit studi
biolog complement cascad
complement cascad biolog extens review compris three
pathway classic mannose-bind lectin altern help regul bodi
innat adapt immun system exhibit pathway follow complex seri
interact complement compon protein regul bodi immun
system system enabl bodi remov foreign organ either
antigen-antibodi detect engag pathogen surfac independ
pathway activ complement activ lead inflamm cell
clearance/elimin membran attack complex -mediat cell death
exhibit overview complement cascad
immunobiolog immun system diseas janeway ca jr et al
classic pathway antigen-bound antibodi encourag complement
complex bind igg igm via fragment crystalliz fc region exhibit
turn set forward seri interact cleav smaller portion
larger portion cleav ultim form convertas
cleav
compar mannose-bind lectin mbl pathway pathway mbl-
associ serin proteas bind bacteri sugar residu consequ cleav
convertas similar fashion exhibit
altern pathway spontan hydrolyz aka tick
result cleav factor bba bb factor process
lead initi convertas cleav exhibit
interact factor form convertas amplifi
abund molecul amplif presenc convertas
creat amplifi activ cascad amplif loop
exhibit activ complement cascad via classical/mbl/altern pathway
central role complement cascad
convertas lead cleavag abund
formation/cytolysi combin convertas form
convertas cleav therebi
initi termin pathway format membran attack
complex creat pore lipid bilay cell induc
cytolysi non-nucl cell bacteria red blood cell
opsonization/phagocytosi deposit surfac cell
opson reveal cell destruct phagocyt phagocytosi
anoth consequ complement activ cleavag proinflammatori
mediat attract neutrophil eosinophil and/or mast cell
bodi regul complement
sever molecul help self-regul complement cascad level
mac-inhibitori protein plasma protein factor fh
daf prevent action convertas amplif via remov
bb respect convertas
cleav irrevers promot opson
fh prevent activ cell surfac express regul
inhibit format level
inhibitor inactiv bind prevent activ classic and/or mbl
situat regulatori protein dysfunct bodi immun
respons becom impair lead autoimmun diseas suscept
infect well understood case complement compon defici
defici blockad associ meningococci infect due
inabl opson phagocytos bacterium respect complement
cascad diseas overactiv play character one
three featur cascad inflamm via complement compon
phagocytosi via opson cell lysi via format
paroxysm nocturn hemoglobinuria pnh ultra-rar acquir hematolog
blood disord mediat complement dysregul affect approxim
patient unit pnh occur due somat mutat x-link
phosphatidylinositol glycan complement class pig-a gene piga encod
product gpi-anchor molecul synthesi support express
complement regulatori protein pig-a gene mutat
protein becom underexpress leav red blood cell vulner red blood cell
exhibit pig-a mutat block biosynthesi anchor express c-reg protein
pnh patient undergo two type hemolysi intravascular extravascular
intravascular hemolyt case red blood cell suscept format
significantli contribut combin intravascular hemolysi
lower life normal patient sever anemia exhibit
notaro sica seminar hematolog
risitano rotoli biolog therapi
due sever anemia hemolyt activ patient experi heavi fatigu
risk thrombot event respons extrem poor
mortal prior eculizumab moreov morbid mortal
enhanc presenc free hemoglobin lyse rbc scaveng nitric
oxid exhibit nitric oxid deplet associ number deleteri effect
bodi includ endotheli cell dysfunct impair regul smooth muscl
tone intravascular thrombosi effect manifest common
symptom diseas fatigu abdomin pain erectil dysfunct arteri
exhibit nitric oxid deplet pnh
hill haemolysi pnh deplet nitric oxid
extravascular case deposit red blood cell mark phagocytosi
clearanc bodi exhibit due process patient affect
anemia spite concurr treatment prevent intravascular hemolysi
notaro sica seminar hematolog oppenheim co research
present pnh take classic form patient continu
period hemolyt activ due complement activ form coupl bone marrow
failur aplast anemia myelodysplast syndrom myelofibrosi subclin form
patient evid hemolysi thrombosi
emphasi lactat dehydrogenas ldh
patient undergo hemolysi common bio marker diseas
lactat dehydrogenas ldh ldh measur correl activ
lyse cell earli period develop pnh believ
lower ldh rang high upper limit normal uln
rang uln would constitut clinic meaning benefit posit
colleagu retrospect analysi observ dramat mortal
risk signal patient ldh vs
marker bilirubin track similarli direct due
measur ldh wide adopt clinician strong marker
diseas
howev becom lost laser focu ldh second pathway
diseas name intravascular hemolyt one due deposit
surfac red blood cell turnov significantli increas lead anemia
fatigu spite ldh control marker effect reticulocyt immatur
red blood cell increas bodi struggl compens anemia
patient therapi remain elev poorli control
marker diseas grown well understood still note
initi develop path first treatment alexion soliri approv pnh
clinic featur treatment hemoglobin stabil unit transfus
leap forward suffici
first approv treatment pnh eculizumab soliri monoclon
antibodi march phase triumph studi
treatment eculizumab transfusion-depend hemolyt pnh patient treat
weekli four week weekli induct follow everi two week
note time infus period rang minut hour
pediatr set follow treatment patient demonstr hemoglobin
stabil transfus independ versu placebo patient
addit unit transfus eculizumab-tr cohort pack unit
versu placebo median usag zero unit versu placebo unit
perhap compel visual diseas eculizumab action ldh ldh
reduc rang uln exhibit
eculizumab rapid prevent intravascular hemolysi approach normal
observ quit earli induct phase week import note
normal complet achiev popul attribut
potenti subset patient adequ control eculizumab treatment
dose therapi gener
observ confirm alexion phase shepherd
open-label studi observ similar activ relev endpoint
pnh one observ shepherd studi note improv paramet
patient maintain complet inhibit complement activ adjust
dose interv day day per protocol hint earli
limit prescrib dose
enhanc ultomiri
mean enhanc limit eculizumab alexion develop second-
gener ravulizumab ultomiri ravulizumab target epitop
eculizumab significantli enhanc half-lif profil inhibitor design
dose everi week versu week demonstr non-inferior compar
eculizumab therapi nave eculizumab-experienc patient two
phase studi respect measur
includ co-primari endpoint transfus depend ldh normal
well seri relev measur ldh reduct facit-fatigu improv rate
breakthrough hemolysi stabil hb level
respect subgroup analysi data exhibit differ
efficaci observ could attribut small sampl size due
stratif note north america signific variabl due patient
enrol potenti commerci reason avail eculizumab
year extens follow-up result maintain week
exhibit transfus avoid stratifi subgroup
exhibit ldh normal stratifi subgroup
although benefici trend observ includ stark contrast breakthrough
hemolysi event comparison drug may skew ravulizumab
match label dose eculizumab establish
inadequ control overactiv subset patient follow
trend benefit might attribut sole durabl coverag
asid note leap forward significantli less frequent iv infus
administr non-trivi anticip facilit rapid convers pnh
popul year-end
extravascular hemolysisth frontier pnh
despit advanc therapeut focus pnh patient treat
eculizumab struggl reach specif clinic goal pertain ultim
anemia due uncontrol extravascular hemolysi mediat deposit
major patient struggl anemia report collabor hillmen
hill colleagu sponsor apelli exhibit emerg work
signific topic pnh recent year fatal consider
pnh address chronic aspect diseas came relev
exhibit persist anemia soliris-tr pnh popul
analysi pnh popul extent unrel aspect
eculizumab therapi requir dose approv label dose due
incomplet coveragepotenti due patient-specif characterist
weight exhibit view ultomiri enhanc half-lif could feasibl address
challeng inadequ dose mechanist target
epitop eculizumab address extravascular hemolysi
exhibit uk assess patient requir eculizumab treatment beyond standard label
check physician treat asian ethnic patient better
control flat label dose due popul weight extravascular
hemolysi remain challeng significantli affect approxim
practic moreov survey treat physician note half physician
would seek therapi improv efficaci standard care eculizumab
geograph atrophi ga sever form dri age-rel macular degener
affect approxim million peopl unit character
progress loss retina pigment epithelium rpe photoreceptor
choriocapillari ga one common caus vision loss industri
world without approv therapi earli period patient present
drusen deposit lipid protein aggreg retina diseas
progress atroph lesion form start initi peripheri eventu begin
affect fovea visual acuiti highest foveal spare transit
non-centr ga central ga estim take median year highlight
rapid ga lead eventu blind loss central vision exhibit
exhibit progress geograph atrophi
boyer et al journal retin vitreou diseas
pathophysiolog believ associ complement cascad
overactiv wherein pro-inflammatori compon caus retin cell
damag addit deposit activ macrophag microglia
respons lead cell remov activ initi control
bodi natur process run hypothesi becom dysregul
time bodi age preclin mous model chang specif complement
gene cfh demonstr host cell termin ga-lik effect
complement activ observ number studi sever
complement inhibitor previous investig treat diseas one meta-
analysi patient highlight polymorph cfh cfi
associ high risk moreov advanc patient held increas level
complement activ product donor eye deposit well
revisit lampalizumab past ga
consid investor familiar surpris us
pnh becom prime exampl complement-medi diseas howev
remind investor ga previous gain attent roch develop
program lampalizumab factor inhibitor focus target altern
pathway conduct though subsequ fail
anti-factor antibodi lampalizumab aim inhibit altern pathway
contribut progress geograph atrophi base phase mahalo
result drug believ effect cfi-posit ga patient subset
enrol phase popul motiv invest two larg phase studi
howev upon complet two phase studi spectri chroma littl effect
ga progress observ cfi-pati subset exhibit note
lampalizumab studi underscor hard-to-treat natur ga
exhibit result phase lampalizumab program
apelli stori inhibit
base strong evid role diseas compstatin analog
develop inhibit activ progress diseas ga
pnh select bind inhibit cleavag subsequ
interact complement cascad exhibit treatment abl
target activ amplif loop formul administr via
subcutan infus system intravitr inject local
boyer et al journal retin vitreou diseas
exhibit molecul action
present februari janssen bjc et al journal biolog chemistri
complet approach treat pnh
one compel featur program pnh abil reach
entir spectrum pnh patient demonstr clear clinic benefit across
sever popul patient despit laser focu ldh breakthrough
hemolysi intravascular hemolysi certainli becom press issu pnh
patient post- pre- ultomiri approv action
potenti address intravascular hemolysi associ format
also mediat opson extravascular hemolyt
exhibit action inhibit cell death cell remov
apelli conduct two key studi pnh assess safeti efficaci
treatment pnh patient nave phase paddock experienc phase
pharoah eculizumab therapi
phase paddock studi pnh patient nave eculizumab therapi
enrol treat follow treatment patient exhibit
dramat reduct ldh level within normal rang
patient achiev normal day consist eculizumab phase
experi improv hemolyt activ also support
improv mean baselin hemoglobin eventu mean
hemoglobin day result decemb cut-off
note one patient underli ovarian cancer whose condit result ldh
elev anemia believ unrel pnh
exhibit phase paddockdecreas ldh improv hb
also notabl data initi present detail individu
experi first eight patient time exhibit appropri control
extravascular hemolysi patient abl arriv hemoglobin level
normal rang note subsequ cut data
two patient believ arriv adequ exposur receiv transfus
one day anoth week
exhibit phase paddockindividu improv hb
consid soliri foothold treatment landscap apelli conduct pharoah
investig activ add-on therapi pnh patient inadequ
respons eculizumab patient present signific detriment
paramet pnh even dose beyond label dose eculizumab highlight
blue exhibit despit increas dose patient reach normal
across measur hb ldh bilirubin reticulocyt also note patient
demonstr ldh normal measur diseas remain
exhibit baselin characterist pharoah popul
treatment co-administr correspond rapid improv
hemoglobin reduct transfus normal ldh two patient
requir transfus note one patient treatment due investig
biliari obstruct post-discontinu eventu
discontinu due pregnanc month treatment anoth morbid obes
improv increas dose subsequ discontinu
despit patient discontinu studi physician sinc
request resumpt treatment
exhibit baselin characterist pharoah popul
look patient purpl line exhibit also uncov meaning effect
withdrawn combin treatment
exhibit patient experi withdraw
among four continu studi four patient eculizumab treatment
success withdrawn septemb data cut-off exhibit
exhibit result four switch patient pharoah
pegasusaddress unmet need head-on
phase pegasu studi open-label random head-to-
head studi design compar treatment eculizumab therapi pnh
patient hemoglobin level less studi patient given
combin treatment eculizumab one-month run-in point
therapi withdrawn random fashion group receiv treatment
group receiv eculizumab infus primari endpoint studi assess
chang hemoglobin four month week secondari measur
reticulocyt ldh facit-fatigu score exhibit studi
administ twice weekli everi three day ensur adequ dose compar
eculizumab
june apelli report complet enrol studi patient
half transfusion-depend note patient studi enrol stabl
dose eculizumab independ label isol true
unmet need pnh address via increas dose
base result pegasu apelli consid potenti file approv
base singl phase experi scenario therapi demonstr
rel improv hemoglobin scenario treatment lead
benefit reduct transfus second phase studi eculizumab
nave patient plan exhibit studi assess hemoglobin
stabil defin avoid decreas hb level baselin
absenc transfus week estim patient expect
enrol random detect differ hemoglobin stabil
reticulocytesth smoke gun superior
readout phase pegasu studi establish clinic
activ pnh patient comparison eculizumab highlight
reticulocyt could defin featur drug rel altern therapi
paramet reticulocyt count remain rel undisclos ravulizumab
howev phase dose escal studi ravulizumab demonstr benefit
level reticulocyt elev baselin european hematolog
associ meet host follow-up data phase experi
ravulizumab one key opinion leader note import disclosur
measur order better compar treatment option other make way toward
approv highlight result paddock pharoah studi
demonstr activ dose pnh patient nave eculizumab treatment
pnh patient alreadi eculizumab co-administr substanti
action anoth dimens diseas exhibit across studi treatment
normal previous elev reticulocyt count within period four
exhibit improv reticulocyt paddock left pharoah right
consid potenti progress pnh diseas bone marrow failur believ
import reticulocyt count could becom major consider physician
long-term complic diseas come focu oppos prior
threat thromboembol event one posit result normal reticulocyt
count suggest allevi hemolyt stress bone marrow
first-in-class treatment ga
given high unmet medic need ga potenti halt overact
complement activ signific potenti apelli conduct sever studi ga
includ recent phase filli studi filli enrol ga
patient treat sham control period addit
treatment period patient also follow period order monitor
progress diseas follow discontinu treatment filli random
patient drug drug sham sham order assess two frequenc
administr monthli everi montheom
patient enrol filli rel well balanc across key paramet ga
follow-up treatment led signific reduct lesion
growth rate monthli cohort demonstr chang baselin
squar root ga lesion growth mm compar pool sham inject
addit treatment eom demonstr posit trend squar root lesion
growth
exhibit phase filli resultssquar root lesion growth time
note initi six-month period lesion growth rate differ
significantli consist potenti need ramp-up period
enabl natur repair eye import featur result also demonstr
behavior placebo arm consist arm phase
six-month off-treat period ga lesion growth similar across arm
prompt need chronic treatment order dampen progress
ga importantli growth prevent observ month month remain
preserv month
furthermor post-hoc analysi ga growth patient fellow treat
eye demonstr encourag trend improv patient treat studi
drug compar sham inject
exhibit filli comparison lesion growth studi fellow
treatment well-toler major advers event balanc across
cohort exhibit one surpris observ filli studi
emerg exud occur dose- frequency-rel manner
although slight imbal rate histori cnv fellow eye
observ monthly-tr cohort exud emerg initi sourc
concern studi exhibit howev upon deeper review patient
note lesion growth fact dampen across patient exhibit
primarili slow mild-to-moder leakag exhibit anoth explan
increas occurr could frequenc physician observ correl
dose frequenc close monitor active-tr patient compar
sham-control one reason phase program design central
reader guid treatment recommend event new onset exud
exhibit phase fillysafeti toler
exhibit filli rate emerg exud studi
exhibit ga lesion growth patient exhibit new-onset exud
could new-onset exud signal repair
angiogenesi meet focu sharpen distinguish type
neovascular nv appear rpe bruch membran
classic form choroid neovascular associ rapid visual
particular evid suggest occult form exud
associ nutrit support retin pigment epithelium outer retina
moreov octa flow pattern fovea seem resist atrophi growth
particularli around fovea
phase studi emerg exud consist type nv
exhibit correl ga progress benefit exhibit import note
improv contribut sole respons improv
observ filli popul level
exhibit comparison exud observ filli versu illustr classic
follow feedback fda apelli establish design phase studi ga
derbi oak exhibit double-mask sham control studi expect
enrol patient random investig monthli
everi month dose primari endpoint studi assess total area ga
lesion base fundu autofluoresc month notabl fda allow
protocol treat exud allow anti-vegf therapi use
combin consid potenti role type neovascular
preserv eye expect extra attent given regard use anti-
vegf therapi situat small cystoid chang may warrant treatment
blind central analyz confirm recommend intervent
phase studi secondari measur phase program includ
function assess read speed microperimetri expect support
potenti commerci ga
exhibit phase derbi oak studi design
follow initi phase studi ga apelli observ occurr non-
infecti inflamm associ impur within singl batch drug
use eight patient four phase ga program four phase wet
safeti studi event resolv apelli suspend phase studi order
identifi manufactur issu implement chang manufactur process
sinc point apelli manufactur two commerci lot new materi without
identifi issu resum enrol expect complet enrol
end
pipelin product statu
addit pnh ga note opportun apelli could delv
complement-medi diseas alreadi phase aiha valid
approach larg proport patient involv look forward
initi phase studi aiha initi data complement depend
nephropathi cdn patient challeng enrol due either
avail altern clinic trial igan rariti scientif basi use
inhibitor robust could lead meaning expans opportun
european hematolog associ meet june apelli report result
updat aiha program result demonstr encourag activ across
warm autoimmun hemolyt anemia waiha patient addit cold
agglutinin diseas cad sole complement-medi activ addit
aiha late-stag pipelin could echo run theme alexion
commerci complement inhibitor soliri ultomiri mani indic
lay beyond pnh gener myasthenia gravi gmg neuromyol optica
spectrum disord nmosd
blockbust opportun within pipelin
two lead indic pnh ga two attract market
could gener blockbust revenu pnh highlight signific
subset patient remain under-control current standard care eculizumab
although potenti superior treatment base target
conserv model penetr subset market estim could
exceed global sale billion reach peak market penetr moreov
follow-up ga could greatli exceed revenu consid potenti similar
ga sever dri market wet one regeneron report us sale
eylea billion wherea novarti report global sale lucenti billion
although anti-vegf treatment target addit indic estim
great major sale primarili driven sale wet achiev market
competit avastin estim price would expect
near-term competit upon potenti approv ga
exhibit revenu opportun pnh ga
million
enter apelli enter period rich catalyst next
phase pegasu readout pnh decemb
phase derbi oak readout ga
initi data expans opportun complement-depend
initi phase studi aiha
updat soliri exclus eu
pnh ga sever complement-target therapi either commerci
develop highlight sever program believ could impact view
treatment landscap diseas next month
ultomiri ravulizumab ultomiri gorilla pnh room
posit potenti altern approach could clinic
patient said believ treat commun pnh quickli adopt
ultomori make market opportun novel treatment requir switch add
futur potenti standard care believ compel advantag
potenti normal hemoglobin control extravascular hemolysi via
could warrant switch patient provid sever result ultomiri switch studi
endpoint futur comparison pegasu month
alexion conduct phase program ultomiri administ
subcutan formul two ml infus devic success
compani anticip potenti approv end addit higher
concentr formul explor reduc iv infus time hour
minut underscor challeng current treatment paradigm
biosimilar amgnrat outperform jay olsen develop abp
biosimilar soliri bind complement pnh ahu order
achiev approv biosimilar product design establish safeti puriti potenc
refer product soliri conduct phase studi abp australia
compar dose abp us eu manufactur soliri
due ultra orphan natur pnh enrol trial investig biosimilar
difficult refer product avail moreov biosimilar potenti may
respect believ avail biosimilar product could support
financi feasibl combin therapi observ pharoah howev
avail biosimilar product hing patent exclus associ soliri
us japan current eu potenti appeal
pozelimab regeneron develop inhibitor pozelimab phase
studi south korea phase studi investig
treatment pozelimab iv sc administr addit pozelimab
regeneron collabor investig
combin treatment rnai therapeut cemdisiran target product
co subsidiari roch develop anti-
antibodi treatment pnh note due differenti epitop
eculizumab switch studi could prove challeng particularli respect ultomori
significantli longer half-lif note mention could also address
small minor patient carri polymorph render eculizumab
ionis-fb-lrx develop ionis-fb-lrx treatment ga
ioni approach rna-target antisens approach inhibit factor product
agent altern pathway drug conduct phase hv studi
plasma fb reduc well toler gsk execut
licens drug roch subsequ enter collabor
develop drug pay million up-front million develop regulatori
commerci milestones/licens fee asset also gener tier royalti
high teen sale drug partner ga rare undisclos
renal condit potenti one pursu apelli phase studi
ga on-going
privat conduct phase trial
modifi vitamin treatment ga vitamin believ
reduc retin toxic improv retin health rodent model diseas
studi enrol patient expect complet primari assess
decemb note avail studi may affect enrol
phase derbi oak studi
hemera bioscienc privat conduct phase studi patient
advanc dri geograph atrophi gene
therapi inject aim increas retin cell express solubl
order prevent format base pathophysiolog unclear
whether inhibit might suffici control progress diseas
may also driven opson phagocytosi retin cell
strength weak opportun threat perspect apelli
invest posit reli strong track record clinic data bode well
upcom data catalyst opportun stori heavili concentr
long-term could broaden discoveri work done addit
compound target complement cascad emerg among apelli
threat known unknown safeti futur competit landscap
target indic could dampen potenti drug commerci howev
time perspect note opportun respect eventu commerci
potenti ga pnh could outpac current conservative-skew assumpt
off-set potenti threat
apelli strength stem robust set clinic data support activ
across three compel indic patient popul previous
unabl demonstr meaning clinic benefit particular improv
hemoglobin associ sign extravascular hemolysi eculizumab-refractori
pnh patient follow switch monotherapi compel ga
larg phase filli studi yet replic compet phase program
replic derbi oak would support approv first ga therapi
view
single-asset stori heavili concentr success clinic catalyst
readout pnh ga potenti aiha hold high convict
readout risk clinic trial execut factor could add risk
readout commerci front pnh transform eculizumab
potenti ravulizumab therapi physician conservat could rais clinic
experi bar prior patient switch
current conserv potenti disrupt pnh market
ascrib market penetr base assess therapeut market
believ compar therapi altern mode deliveri lead rel
share market first market treatment hold typic market
said opportun demonstr superior across number
domain success would constitut greater share second-
to-market option view ravulizumab replac eculizumab ga patient
identif occur rapidli anticip could see address
market grow faster current assumpt
respect threat apelli face two key threat relat competit
previous describ safeti upstream target central
target complement cascad broadli theoret risk heighten
immun suppress remain part stori said apelli
accru patient-year system exposur primarili pnh
continu grow pegasu apelli phase studi potenti phase
studi aiha note head-to-head pegasu studi also serv
import databas compar safeti note safeti concern
primarili pertain hematolog indic requir system exposur
compar ga local administr
late-stag develop compani apelli focus research develop
requir signific capit execut clinic studi fund
oper apelli conduct initi public equiti offer follow secondari
offer march compani hold cash equival balanc
million believ provid cash runway also enter
agreement privat support develop
pnh exchang conting futur payment upon success pnh
base time payment valu sfj liabil risk-adjust basi
million exhibit
exhibit valuat sfj liabil million unless note
march apelli report million common stock warrant option
includ valuat model model futur capit rais order
support futur commerci develop separ indic
dr francoi co-found apelli serv member board
director presid chief execut offic sinc septemb prior co-
found compani dr francoi co-found inc
potentia privat biotechnolog compani dr francoi serv presid
chief execut offic potentia sinc dr francoi receiv
univers leuven belgium ph physiolog univers
louisvil follow postgradu train pediatr transplant surgeri dr francoi
member research team perform first success hand
transplant louisvil face transplant whose work support hand
transplant lyon franc
dr deschatelet co-found novemb join
chief oper offic prior found apelli dr deschatelet co-found potentia
pharmaceut chief oper offic compani sign
licens agreement alcon potentia ocular drug develop program
apelli acquir asset potentia transact close septemb
dr deschatelet engag state-of-the-art research area
surfac chemistri organ synthesi last year co-found
risk-adjust present valu sfj obligationdiscount base sfj liabil million payment million contribut sfj total conserv assum equal payment note back-end load outperform
syntetica fine chemic custom chemic synthesi compani support
pharmaceut industri extens experi nanobiotechnolog
synthesi organ molecul bioconjug dr deschatelet receiv ph
organ chemistri univers montreal post-doctor train
laboratori dr georg whitesid harvard univers
timothi sullivan serv apelli chief financi offic sinc octob
januari octob mr sullivan serv aju ib invest
ventur capit firm led firm invest life scienc compani
prior join aju ib invest decemb januari mr sullivan
manag director head life scienc invest bank rb citizen mr
sullivan observ board director novemb octob
mr sullivan previous serv director inc
inc mr sullivan receiv columbia busi
school biolog harvard univers
dr grossi potentia pharmaceut clinic research director join
apelli new compani clinic research director dr grossi receiv
medic degre univers cordoba argentina doctor degre
physiolog univers louisvil follow post graduat train
surgeri dr grossi join plastic surgeri research laboratori univers
louisvil develop expertis microsurgeri composit tissu
transplant crucial member louisvil face transplant
publish sever manuscript ethic psycholog aspect face
transplant consid hallmark public field also
publish numer articl field ischem precondit composit tissu
adam townsend join apelli chief commerci offic novemb prior
join apelli mr townsend work cambridg
octob progress leadership role commerci corpor
develop recent serv senior vice presid corpor
develop prior mr townsend senior vice presid global market
commerci strategi global respons commerci team involv
late stage commerci product led success launch
multipl blockbust product neurolog rare diseas space prior
held numer leadership posit increas level respons europ
eusa pharma gener manag uk ireland nordic region
head commerci drive signific consist growth across multipl
geographi prior mr townsend work zug part
european market team uk progress head
market began career sale novarti uk receiv sc hon
medic biochemistri univers london uk
stock price compani mention report
statement oper
thousand except per share
good sold
research develop
loss extinguish debt
loss remeasur fair valu warrant deriv
comprehens loss net tax
net loss per common share basic dilut
weight average common share basic dilut
thousand
cash equival
refund research develop credit
properti equip net
liabil stockhold equiti
current portion long-term debt
current portion right use liabil
addit paid capit
accumul comprehens incom
total liabil stockhold equiti
statement cashflow
thousand
loss earli extinguish debt
loss remeasur fair valu warrant
accret discount
refund research develop credit
net cash use oper activ
purchas properti equip
net cash use invest activ
issuanc seri convert prefer stock net
proce issuanc common stock net issuanc
proce develop deriv liabil
proce exercis stock option warrant
proce issuanc term loan net issuanc cost
proce issuanc promissori note payabl
affili stockhold
proce issuanc common stock warrant
repay term loan
net cash provid financ activ
effect exchang rate chang cash cash equival
net increas decreas cash equival
cash equival begin period
cash equival end period
million
patient pnh
pnh patient treat
patient pnh
pnh patient treat
million
patient ga
ga patient treat
adult year age
patient ga
ga patient treat
popul
/share total
million except per share
assumpt multipl tab
nwc revenu
npv
million except per share
